Dicot develops drugs against sexual dysfunction with a large market potential

Dicot's most important product is Libiguin™ for the treatment of erectile dysfunction and premature ejaculation among men, as well as potentially for the treatment of decreased lust. 

Dicot has developed and patented methods for manufacturing of Libiguin™ through a semisynthetic method.

Dicot also has patented the Libiguin™ substance itself.

In pre-clinical tests, Libiguin™ has shown effects in very low doses, giving a remarkable long-lasting effect. The long-lasting effect eliminates the need for pre-planning to take medication before sexual activity, which is generally the case with current treatments.

More news